Pharmacological Effect of Berberine on Alzheimer's Disease： A Review
10.13422/j.cnki.syfjx.20240741
- VernacularTitle:小檗碱治疗阿尔茨海默病的药理作用研究进展
- Author:
Xuejing WANG
1
;
Guangcheng ZHONG
1
;
Shuting LI
1
;
Qian ZHANG
1
;
Bojie LUO
1
;
Qi WANG
1
Author Information
1. Science and Technology Innovation Center， Guangzhou University of Chinese Medicine， Guangzhou 510405， China
- Publication Type:Journal Article
- Keywords:
berberine;
Alzheimer's disease;
amyloid-β;
Tau protein;
neuroinflammation
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2025;31(2):286-294
- CountryChina
- Language:Chinese
-
Abstract:
Alzheimer's disease （AD）， a degenerative disease of the central nervous system， is characterized by progressive degradation of learning， memory， and cognitive functions. Currently， few drugs are available for treating AD， and their effects are limited. Berberine （BBR） is a natural isoquinoline （quaternary ammonium-like） with a wide range of pharmacological effects. Studies have proven that BBR has good potential in the treatment of AD. Specifically， BBR can inhibit the generation， aggregation， and neurotoxicity of amyloid-β and the hyperphosphorylation of Tau protein， promote the clearance of phosphorylated Tau protein， reduce the cholinesterase activity， neuroinflammation， and oxidative stress， regulate neuronal apoptosis， improve the mitochondrial function and glucose and lipid metabolism， suppress the monoamine oxidase activity， and modulate gut microbiota. In addition， researchers have ameliorated the low bioavailability of BBR. Probing into the potential targets is hoped to provide a reference for further research on the prevention and treatment of AD by BBR.
